Ichosia Biotechnology is developing a method of mass-producing laboratory grown red blood cells (RBCs) to make blood safer, less expensive and more reliable for clinical transfusions.
The world is in desperate need of a donor blood substitute as shortages are significant, costs are growing, and contamination is always a risk. Ichosia’s product, ErythrosynTM, is a genetically-enhanced, laboratory-grow RBC which will be producible on demand, pathogen-free, and universally compatible. Our vision is that once this technology is full... Read more
